Novavax (NVAX) ended the recent trading session at $10, demonstrating a -1.19% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.92%. At ...

智通财经APP注意到，周三美股盘前，诺瓦瓦克斯医药(NVAX.US)股价一度跌近30%，此前美国FDA暂停了其COVID-19和流感联合疫苗以及独立流感候选疫苗的新药申请，理由是一名试验参与者出现严重不良事件。截至发稿，诺瓦瓦克斯医药跌16.83%， ...

10月16日｜诺瓦瓦克斯(NVAX.US) 盘前大跌逾31%，美国食品药品监督管理局（FDA）暂时搁置公司新冠流感疫苗临床试验申请，对此，诺瓦瓦克斯医药表示，临床暂停是因为单个CIC 2期试验参与者发生了严重的运动神经病变事件的自发报告。

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

智通财经APP获悉，周三，诺瓦瓦克斯医药 (NVAX.US)股价大幅下跌，截至发稿，该股跌超19%，报10.16美元。消息面上，美国食品药品监督管理局 (FDA)暂停了该公司计划进行的流感疫苗临床试验，临床暂停是因为单个CIC ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a ...

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.

周三，诺瓦瓦克斯医药(NVAX.US)股价大幅下跌，截至发稿，该股跌超19%，报10.16美元。消息面上，美国食品药品监督管理局(FDA)暂停了该公司计划进行的流感疫苗临床试验，临床暂停是因为单个CIC2期试验参与者发生了严重的运动神经病变事件的自发报告。

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.